← Leaderboards
Wen Xue
Massachusetts Institute Of Technology
$13,355,481
Attributed
$18,041,471
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,041,471 · 10
By mechanism
P01$5,176,331 · 3
R01$3,746,135 · 2
UH3$2,938,558 · 1
UG3$2,700,237 · 1
DP2$2,512,500 · 1
R00$747,000 · 1
Top collaborators
- Daniel G Anderson6 shared
- Guang-Ping Gao6 shared
- Erik J Sontheimer4 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Daniel G Anderson$11,913,058
- Daniel John Siegwart$5,179,626
- Victoria Jane Madigan$209,964
- Zackery Ely$30,058
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoGenesLungMutationClustered Regularly Interspaced Short Palindromic RepeatsRepairedLiverMouse ModelTechnologyMediatingGuide RnaAdultSafetyCrispr/Cas TechnologyCell TypeGenome EditingPhenotypeIn Vivo ModelDependovirusAllelesGene CorrectionCellsCapsidGene Therapy
Grant awards (29)
In vivo prime editing for precision cancer mouse models$672,615
R01 · FY2025 · CA · contact PI
Advanced Delivery Platforms for Base Editing In Vivo$583,738
R01 · FY2025 · GM
Editing of the AAT locus using novel base editing and prime editing technologies$544,375
P01 · FY2025 · HL · contact PI
Advanced Delivery Platforms for Base Editing In Vivo$102,372
R01 · FY2025 · GM
In vivo prime editing for precision cancer mouse models$594,327
R01 · FY2024 · CA · contact PI
Advanced Delivery Platforms for Base Editing In Vivo$583,738
R01 · FY2024 · GM
Editing of the AAT locus using novel base editing and prime editing technologies$536,581
P01 · FY2024 · HL · contact PI
In vivo prime editing for precision cancer mouse models$625,607
R01 · FY2023 · CA · contact PI
Advanced Delivery Platforms for Base Editing In Vivo$583,738
R01 · FY2023 · GM
Editing of the AAT locus using novel base editing and prime editing technologies$544,375
P01 · FY2023 · HL · contact PI
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$1,660,678
UH3 · FY2022 · HL
Editing of the AAT locus using novel base editing and prime editing technologies$544,375
P01 · FY2022 · HL · contact PI
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$1,277,880
UH3 · FY2021 · HL
Editing of the AAT locus using novel base editing and prime editing technologies$544,375
P01 · FY2021 · HL · contact PI
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$795,706
UG3 · FY2020 · HL
Liver-directed somatic gene correction rAAV system of regulatable Cas9/sgRNA$502,500
P01 · FY2020 · HL · contact PI
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$802,570
UG3 · FY2019 · HL
Liver-directed somatic gene correction rAAV system of regulatable Cas9/sgRNA$502,500
P01 · FY2019 · HL · contact PI
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$275,792
UG3 · FY2019 · HL
Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$826,169
UG3 · FY2018 · HL
Liver-directed somatic gene correction rAAV system of regulatable Cas9/sgRNA$477,375
P01 · FY2018 · HL · contact PI
Liver-directed somatic gene correction rAAV system of regulatable Cas9/sgRNA$477,375
P01 · FY2017 · HL · contact PI
CRISPR-based modular therapy for precision medicine$2,512,500
DP2 · FY2016 · HL · contact PI
Liver-directed somatic gene correction rAAV system of regulatable Cas9/sgRNA$502,500
P01 · FY2016 · HL · contact PI
Investigating microRNA miR-34a in lung cancer development and therapy$249,000
R00 · FY2016 · CA · contact PI
Investigating microRNA miR-34a in lung cancer development and therapy$249,000
R00 · FY2015 · CA · contact PI
Investigating microRNA miR-34a in lung cancer development and therapy$249,000
R00 · FY2014 · CA · contact PI
Investigating microRNA miR-34a in lung cancer development and therapy$110,355
K99 · FY2013 · CA · contact PI
Investigating microRNA miR-34a in lung cancer development and therapy$110,355
K99 · FY2012 · CA · contact PI